Cargando…
2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
BACKGROUND: Gram-negative (GN) bacterial resistance is a major global health problem. Cefiderocol (CFDC) is active against Pseudomonas aeruginosa (PA). PROVE is an international, retrospective study of CFDC use in Gram-negative infections (GNI). This analysis examines outcomes by infection site and...
Autores principales: | Marcella, Stephen, Cai, Bin, Friedman, Bruce, Verardi, Stefano, Gozalo, Laurence, Slover, Christine M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678517/ http://dx.doi.org/10.1093/ofid/ofad500.2361 |
Ejemplares similares
-
2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023) -
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023) -
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022) -
1291. PROVE (Retrospective Cefiderocol Chart Review) Study of Real-World Outcomes and Safety in the Treatment of Patients with Gram-negative Bacterial Infections in the US and Europe
por: Marcella, Stephen, et al.
Publicado: (2021) -
648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)